 | • レポートコード：TPM-NV172 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、173ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、敗血症治療法の世界市場について調べ、敗血症治療法の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（アミノグリコシド、セファロスポリン、糖ペプチド抗生物質、その他）分析、投与経路別（静脈内、経口）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・敗血症治療法の市場概要 ・敗血症治療法の市場動向 ・敗血症治療法の世界市場規模・予測 ・敗血症治療法市場：薬物クラス別（アミノグリコシド、セファロスポリン、糖ペプチド抗生物質、その他） ・敗血症治療法市場：投与経路別（静脈内、経口） ・敗血症治療法市場：投与経路別（静脈内、経口） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.
Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an ‘in vitro’ bactericidal activity against vibrio vulnificus.
Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sepsis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sepsis Therapeutics Market Analysis and Forecasts, 2017–2027
5. Market Outlook
5.1. Regulatory Scenario
5.2. Pipeline Analysis
6. Global Sepsis Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Aminoglycosides
6.3.2. Cephalosporin
6.3.3. Glycopeptide Antibiotics
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Sepsis Therapeutics Market Analysis and Forecasts, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2027
7.3.1. Intravenous
7.3.2. Oral
7.4. Market Attractiveness, by Route of Administration
8. Global Sepsis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Sepsis Therapeutics Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Sepsis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Aminoglycosides
10.2.2. Cephalosporin
10.2.3. Glycopeptide Antibiotics
10.2.4. Others
10.3. Market Value Forecast, by Route of Administration, 2017–2027
10.3.1. Intravenous
10.3.2. Oral
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Sepsis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Aminoglycosides
11.2.2. Cephalosporin
11.2.3. Glycopeptide Antibiotics
11.2.4. Others
11.3. Market Value Forecast, by Route of Administration, 2017–2027
11.3.1. Intravenous
11.3.2. Oral
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Sepsis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Aminoglycosides
12.2.2. Cephalosporin
12.2.3. Glycopeptide Antibiotics
12.2.4. Others
12.3. Market Value Forecast, by Route of Administration, 2017–2027
12.3.1. Intravenous
12.3.2. Oral
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Sepsis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Aminoglycosides
13.2.2. Cephalosporin
13.2.3. Glycopeptide Antibiotics
13.2.4. Others
13.3. Market Value Forecast, by Route of Administration, 2017–2027
13.3.1. Intravenous
13.3.2. Oral
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Sepsis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Aminoglycosides
14.2.2. Cephalosporin
14.2.3. Glycopeptide Antibiotics
14.2.4. Others
14.3. Market Value Forecast, by Route of Administration, 2017–2027
14.3.1. Intravenous
14.3.2. Oral
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Mylan N.V.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.1.5. Financial Overview
15.2.2. Asahi Kasei Corporation
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.2.5. Financial Overview
15.2.3. Pfizer, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.3.5. Financial Overview
15.2.4. GlaxoSmithKline plc
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.4.5. Financial Overview
15.2.5. RegeneRx
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.5.5. Financial Overview
15.2.6. Adrenomed AG
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Strategic Overview
15.2.7. AtoxBio
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8. ENDACEA, INC.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Strategic Overview
15.2.9. INOTREM S.A
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Strategic Overview